Effect of epirubicin combined with docetaxel neoadjuvant chemotherapy on Ki-67 of breast cancer
表柔比星联合多西他赛新辅助化疗对乳腺癌Ki-67的影响

摘要

在女性常见的恶性肿瘤之中，乳腺癌属于相对常见的类型之一，大多患者通过触摸到乳腺结节或体检而发现疾病，在出现相应的临床表现或体征时恶性肿瘤已较晚期。现阶段对于乳腺癌的主要治疗措施之一包括新辅助化疗。新辅助化疗是在患者接受手术或是放疗等局部治疗前所接受的首次全身的治疗。经过长期的实践发现，接受新辅助化疗的患者，乳腺癌患者的病理分期更低，对于提升患者手术切除率、保乳成功率，抑制转移病灶、评估相关化疗药物的敏感性等方面均具有积极的意义。近年来，随着研究的不断深入，发现细胞增殖核抗原（Ki-67）能够有效的反应患者细胞增殖的活性，同时国内有研究指出：个体化的精准化疗方案能够有效的改善患者病情，延长患者生存期，但仍未得出明确的定论，，本文将探究分析表柔比星联合多西他赛新辅助化疗治疗乳腺癌对癌组织Ki-67的影响。

Abstract

Among the common malignant tumors in women, breast cancer is one of the relatively common types, most patients find the disease by touching breast nodules or physical examination, and the malignant tumor is advanced when the corresponding clinical manifestations or signs appear. One of the main treatment measures for breast cancer at this stage includes neoadjuvant chemotherapy. Neoadjuvant chemotherapy is the first systemic treatment that a patient receives before undergoing local therapy such as surgery or radiation therapy. After long-term practice, it has been found that patients receiving neoadjuvant chemotherapy have lower pathological stages in breast cancer patients, which has positive significance for improving the surgical resection rate, breast conserving success rate, inhibition of metastasis, and assessing the sensitivity of related chemotherapy drugs. In recent years, with the deepening of research, it has been found that cell proliferation nuclear antigen (Ki-67) can effectively reflect the activity of cell proliferation of patients, and domestic studies have pointed out that individualized precision chemotherapy regimen can effectively improve the patient's condition and prolong the survival of the patient, but there is still no clear conclusion, this article will explore and analyze the effect of epirubicin combined with docetaxel neoadjuvant chemotherapy on cancer tissue Ki-67.